Zentalis Pharmaceuticals, Inc.
NASDAQ Global MarketTotal Valuation
Zentalis Pharmaceuticals, Inc. carries a market capitalization of 264.81M, placing it among publicly traded companies globally. Its enterprise value stands at -9.88M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 264.81M |
| Enterprise Value | -9.88M |
Share Statistics
Zentalis Pharmaceuticals, Inc. currently has 71.16M shares outstanding.
| Shares Outstanding | 71.16M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.14 |
| P/TBV Ratio | 0.92 |
| P/FCF Ratio | -1.33 |
| P/OCF Ratio | -1.33 |
Financial Position
Zentalis Pharmaceuticals, Inc. maintains a current ratio of 6.19, meaning it holds 6.2x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 6.19 |
| Quick Ratio | 6.01 |
| Debt / Equity | 18.97 |
| Debt / EBITDA | -0.24 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -38.97 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | 562,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Zentalis Pharmaceuticals, Inc.'s stock has gained approximately 148% over the past 52 weeks. The 50-day moving average sits at 3.84, while the 200-day moving average is 2.39.
| Beta (5Y) | N/A |
| 52-Week Price Change | 148% |
| 50-Day Moving Average | 3.84 |
| 200-Day Moving Average | 2.39 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -144.41M, while operating income came in at -145.04M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -145.04M |
| Pretax Income | -123.57M |
| Net Income | -124.13M |
| EBITDA | -144.41M |
| EBIT | -145.04M |
| Earnings Per Share (EPS) | -1.74 |
Balance Sheet
Zentalis Pharmaceuticals, Inc. holds 211.76M in cash and equivalents against 34.65M in total debt, resulting in a net debt position of -31.93M. Total book value stands at -1.23B, with working capital of 182.86M providing operational flexibility.
| Cash & Cash Equivalents | 211.76M |
| Total Debt | 34.65M |
| Net Debt | -31.93M |
| Equity (Book Value) | -1.23B |
| Book Value Per Share | -17.17 |
| Working Capital | 182.86M |
Cash Flow
Zentalis Pharmaceuticals, Inc. produced -125.57M in operating cash flow over the past twelve months. After subtracting -34,000.00 in capital expenditures, free cash flow totaled -125.60M - equivalent to -1.76 per share.
| Operating Cash Flow | -125.57M |
| Capital Expenditures | -34,000.00 |
| Free Cash Flow | -125.60M |
| FCF Per Share | -1.76 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 3.35 |
| FCF Yield | -75.07 |
Scores
Zentalis Pharmaceuticals, Inc. posts an Altman Z-Score of -6.39, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -6.39 |